0000950170-24-083928.txt : 20240716 0000950170-24-083928.hdr.sgml : 20240716 20240716161527 ACCESSION NUMBER: 0000950170-24-083928 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240711 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240716 DATE AS OF CHANGE: 20240716 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Relay Therapeutics, Inc. CENTRAL INDEX KEY: 0001812364 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39385 FILM NUMBER: 241119819 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-370-8837 MAIL ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 rlay-20240711.htm 8-K 8-K
0001812364false00018123642024-07-112024-07-11

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2024

 

 

RELAY THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39385

47-3923475

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

399 Binney Street

 

Cambridge, Massachusetts

 

02139

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 370-8837

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

RLAY

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.02 Termination of a Material Definitive Agreement.

On July 11, 2024, Relay Therapeutics, Inc. (the “Company”) received notice of termination of the Collaboration and License Agreement, dated December 11, 2020, as amended from time to time (the “Agreement”), with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively, “Genentech”). Genentech elected to terminate the Agreement without cause, and the termination will become effective 180 days after the date of receipt of the notice of termination (the “Termination Date”).

Under the Agreement, the Company and Genentech (each a “Party” and together, the “Parties”) collaborate on the development and commercialization of RLY-1971 (now referred to as migoprotafib or GDC-1971), the Company’s oral, small molecule inhibitor of Src homology region 2 domain-containing phosphatase-2. Under the terms of the Agreement, the Company received aggregate consideration of $121.8 million from Genentech, including $75.0 million in an upfront payment, $45.0 million in milestone payments as well as reimbursement of certain research and development costs.

As a result of the termination of the Agreement, the Company will not be entitled to receive any further milestones or other payments due after the Termination Date. The Parties will also cease to have any development or commercialization obligations after the Termination Date and the licenses the Company granted to Genentech pursuant to the Agreement will cease to be in effect as of the Termination Date. Other material terms of the Agreement not related to termination are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

The foregoing description of the termination of the Agreement is only a summary of the material terms thereof, and does not purport to be complete. The description is qualified in its entirety by reference to the Agreement which the Company filed as Exhibits 10.17 and 10.18 to its Annual Report on Form 10-K for the year ending December 31, 2023.

Item 9.01 Financial Statements and Exhibits.

 

(d)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

RELAY THERAPEUTICS, INC.

 

 

 

 

Date:

July 16, 2024

By:

/s/ Brian Adams

 

 

 

Brian Adams
Chief Legal Officer

 

 EX-101.SCH 2 rlay-20240711.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Document And Entity Information
Jul. 11, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 11, 2024
Entity Registrant Name RELAY THERAPEUTICS, INC.
Entity Central Index Key 0001812364
Entity Emerging Growth Company false
Entity File Number 001-39385
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-3923475
Entity Address, Address Line One 399 Binney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 370-8837
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol RLAY
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports rlay-20240711.htm rlay-20240711.xsd http://xbrl.sec.gov/dei/2024 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rlay-20240711.htm": { "nsprefix": "rlay", "nsuri": "http://relaytx.com/20240711", "dts": { "inline": { "local": [ "rlay-20240711.htm" ] }, "schema": { "local": [ "rlay-20240711.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_9ab41d4a-854d-4f9e-ba73-33218085d18d", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rlay-20240711.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ab41d4a-854d-4f9e-ba73-33218085d18d", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rlay-20240711.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://relaytx.com/20240711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-083928-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-083928-xbrl.zip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rlay-20240711_htm.xml IDEA: XBRL DOCUMENT 0001812364 2024-07-11 2024-07-11 0001812364 false 8-K 2024-07-11 RELAY THERAPEUTICS, INC. DE 001-39385 47-3923475 399 Binney Street Cambridge MA 02139 (617) 370-8837 false false false false Common Stock, par value $0.001 per share RLAY NASDAQ false